CLINICAL AND ECONOMIC BURDEN OF HOSPITALIZATION FOR EXACERBATION OR CRISIS AMONG PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN THE UNITED STATES
Author(s)
Jacqueline Pesa, MS, MSPH, PhD1, Maryia Zhdanava, MA2, Louis Jackson, BS, PharmD3, Paul Boonmak, PhD, MD4, Anabelle Tardif-Samson, MA5, Fanny Jiang, MS6, Dominic Pilon, MA2.
1Johnson and Johnson, superior, CO, USA, 2Analysis Group, Inc., Montréal, QC, Canada, 3Johnson and Johnson, Media, PA, USA, 4Groupe d'analyse, Ltée, Montreal, QC, Canada, 5Analysis Group, Inc., Montreal, QC, Canada, 6Analysis Group, Inc., Toronto, ON, Canada.
1Johnson and Johnson, superior, CO, USA, 2Analysis Group, Inc., Montréal, QC, Canada, 3Johnson and Johnson, Media, PA, USA, 4Groupe d'analyse, Ltée, Montreal, QC, Canada, 5Analysis Group, Inc., Montreal, QC, Canada, 6Analysis Group, Inc., Toronto, ON, Canada.
OBJECTIVES: Hospitalizations for generalized myasthenia gravis (gMG) exacerbations or crises reflect severe disease activity, yet their clinical and economic burden is poorly understood. This study described hospitalization and re-hospitalization characteristics and post-discharge treatments among patients hospitalized for gMG-related events in the US.
METHODS: Adults first hospitalized (index date) for a gMG-related event were identified from the Komodo Research Database (01/2017-05/2025). Exacerbations were defined based on diagnoses for MG with exacerbation in the primary position. Crises were defined based on claims for airway management with any MG diagnosis in any position. Baseline characteristics were described 12 months pre-index. Follow-up spanned index until end of continuous insurance eligibility or data. Costs were adjusted to 2025 US dollars.
RESULTS: 1,964 patients were hospitalized for an MG-related event (mean age: 64.7 years; 47.5% female; median follow-up: 16.8 months); 82.3% of hospitalizations were for exacerbations, and 17.7% for crises. Mean length of stay was 14.1 days; during index hospitalization, 53.3% required an intensive care unit (ICU) admission, 19.4% received plasmapheresis, 6.8% immunoglobulin, and 77.7% inpatient rehabilitation. Mean total hospitalization costs were $39,244; mean ICU and rehabilitation costs were $35,935 and $31,295, respectively. Within 30 days of discharge, 68.2% received ≥1 acetylcholinesterase inhibitor, systemic corticosteroid, or non-steroidal immunosuppressant; 12.4% received immunoglobulin; 2.1% received a neonatal Fc receptor blocker, and 1.3% received a complement C5 inhibitor. Re-hospitalization for a gMG-related event occurred in 30.0%; 17.6% within 90 days. Among re-hospitalizations, 84.7% were for exacerbations, and 15.3% for crises; 50.0% required an ICU admission; mean total re-hospitalization costs were $35,986.
CONCLUSIONS: In the US, among patients hospitalized for gMG-related events, substantial clinical and economic burden and frequent recurrence were observed within three months post-discharge. Findings highlight the need for strategies to reduce hospitalization and re-hospitalization in gMG.
METHODS: Adults first hospitalized (index date) for a gMG-related event were identified from the Komodo Research Database (01/2017-05/2025). Exacerbations were defined based on diagnoses for MG with exacerbation in the primary position. Crises were defined based on claims for airway management with any MG diagnosis in any position. Baseline characteristics were described 12 months pre-index. Follow-up spanned index until end of continuous insurance eligibility or data. Costs were adjusted to 2025 US dollars.
RESULTS: 1,964 patients were hospitalized for an MG-related event (mean age: 64.7 years; 47.5% female; median follow-up: 16.8 months); 82.3% of hospitalizations were for exacerbations, and 17.7% for crises. Mean length of stay was 14.1 days; during index hospitalization, 53.3% required an intensive care unit (ICU) admission, 19.4% received plasmapheresis, 6.8% immunoglobulin, and 77.7% inpatient rehabilitation. Mean total hospitalization costs were $39,244; mean ICU and rehabilitation costs were $35,935 and $31,295, respectively. Within 30 days of discharge, 68.2% received ≥1 acetylcholinesterase inhibitor, systemic corticosteroid, or non-steroidal immunosuppressant; 12.4% received immunoglobulin; 2.1% received a neonatal Fc receptor blocker, and 1.3% received a complement C5 inhibitor. Re-hospitalization for a gMG-related event occurred in 30.0%; 17.6% within 90 days. Among re-hospitalizations, 84.7% were for exacerbations, and 15.3% for crises; 50.0% required an ICU admission; mean total re-hospitalization costs were $35,986.
CONCLUSIONS: In the US, among patients hospitalized for gMG-related events, substantial clinical and economic burden and frequent recurrence were observed within three months post-discharge. Findings highlight the need for strategies to reduce hospitalization and re-hospitalization in gMG.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE360
Topic
Economic Evaluation, Epidemiology & Public Health, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Neurological Disorders, Rare & Orphan Diseases